We are live on ! Find out more
RIGL icon

Rigel Pharmaceuticals
RIGL

99 hedge funds and large institutions have $357M invested in Rigel Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 35 increasing their positions, 30 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

70% more capital invested

Capital invested by funds: $210M → $357M (+$146M)

41% more call options, than puts

Call options by funds: $148K | Put options by funds: $105K

17% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 30

0.09% less ownership

Funds ownership: 8.92% → 8.83% (-0.09%)

7% less funds holding

Funds holding: 107 → 99 (-8)

13% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 16

Holders
99
Holders Change
-8
Holders Change %
-7.48%
% of All Funds
2.46%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.05%
New
14
Increased
35
Reduced
30
Closed
16
Calls
$148K
Puts
$105K
Net Calls
+$43K
Net Calls Change
+$103K

Top Buyers

1
BlackRock
BlackRock
New York
+$25.8M
2
GPP
Great Point Partners
Connecticut
+$23.2M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$8.93M
4
Wellington Management Group
Wellington Management Group
Massachusetts
+$8.36M
5
Millennium Management
Millennium Management
New York
+$3.76M

Top Sellers

1
Citadel Advisors
Citadel Advisors
Florida
-$7.32M
2
CAM
Cormorant Asset Management
Massachusetts
-$2.21M
3
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$1.36M
4
Goldman Sachs
Goldman Sachs
New York
-$1.08M
5
CS
Credit Suisse
Switzerland
-$1.03M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$60.7M +$8.93M +350,246 +24%
Wellington Management Group
2
Wellington Management Group
Massachusetts
$45.8M +$8.36M +328,239 +31%
BlackRock
3
BlackRock
New York
$33.6M +$25.8M +1,014,258 +47,022%
GPP
4
Great Point Partners
Connecticut
$30.1M +$23.2M +910,569 New
Vanguard Group
5
Vanguard Group
Pennsylvania
$18.8M +$2.45M +96,035 +20%
O
6
OppenheimerFunds
New York
$16.6M +$4K +157 +0%
PAI
7
Palo Alto Investors
California
$14.1M +$199K +7,800 +2%
NMC
8
NEA Management Company
Maryland
$10.4M – – –
Millennium Management
9
Millennium Management
New York
$10.1M +$3.76M +147,661 +95%
T. Rowe Price Associates
10
T. Rowe Price Associates
Maryland
$9.12M +$2.65M +103,980 +61%
BBA
11
Baker Bros. Advisors
New York
$8.34M +$1.27M +50,000 +25%
State Street
12
State Street
Massachusetts
$6.95M +$984K +38,599 +23%
CAM
13
Cormorant Asset Management
Massachusetts
$6.62M -$2.21M -86,870 -30%
SCM
14
Sio Capital Management
New York
$6.25M +$1.59M +62,479 +49%
MWNA
15
Marshall Wace North America
New York
$5.93M +$5.04M +197,833 New
D.E. Shaw & Co
16
D.E. Shaw & Co
New York
$5.36M +$417K +16,349 +11%
JP Morgan Chase
17
JP Morgan Chase
New York
$4.8M -$851K -33,378 -19%
Northern Trust
18
Northern Trust
Illinois
$4.51M +$649K +25,459 +23%
RPAM
19
Rhenman & Partners Asset Management
Sweden
$4.24M – – –
GTC
20
Ghost Tree Capital
New York
$3.64M +$1.02M +40,000 +57%
CS
21
Candriam SCA
Luxembourg
$3.59M +$1.2M +47,000 +76%
Dimensional Fund Advisors
22
Dimensional Fund Advisors
Texas
$3.39M -$421K -16,534 -14%
Geode Capital Management
23
Geode Capital Management
Massachusetts
$3.35M +$639K +25,057 +33%
RSCM
24
Rock Springs Capital Management
Maryland
$3.31M – – –
California Public Employees Retirement System
25
California Public Employees Retirement System
California
$2.92M – – –
1
2 3 4 5

RIGL Hedge Fund Activity: Q1 2017 in Review

99 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q1 2017, worth a combined $357M — up 70% from $210M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of RIGL and 14 opened new positions — a net loss of 2 holders — while 30 trimmed existing stakes and 35 added.

The largest buyer was BlackRock, adding an estimated $25.8M. The largest seller was Citadel Advisors, cutting an estimated $7.32M.

  • 99 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q1 2017, down from 107 in Q4 2016.
  • Funds reported $357M of Rigel Pharmaceuticals stock for Q1 2017, up 70% quarter-over-quarter.
  • 14 funds opened new Rigel Pharmaceuticals positions in Q1 2017 and 16 closed out, a net change of -2 holders.
  • The largest Rigel Pharmaceuticals buyer in Q1 2017 was BlackRock, an estimated $25.8M added.
  • The largest Rigel Pharmaceuticals seller in Q1 2017 was Citadel Advisors, an estimated $7.32M sold.

Based on aggregated 13F filings for Q1 2017.